Nguyen Pham is an associate in the technology transactions practice at Wilson Sonsini Goodrich & Rosati. Nguyen advises life sciences and technology companies on legal and business issues associated with the development, manufacture, and commercialization of their products, services, and intellectual property assets. Her practice focuses on representing public and private companies, including start-ups, in complex partnering and licensing arrangements, mergers and acquisitions, spin-outs, collaboration agreements, license agreements with academic and nonprofit institutions, research and development agreements, clinical trial agreements, and manufacturing, supply, and distribution agreements.
Nguyen Pham is an associate in the technology transactions practice at Wilson Sonsini Goodrich & Rosati. Nguyen advises life sciences and technology companies on legal and business issues associated with the development, manufacture, and commercialization of their products, services, and intellectual property assets. Her practice focuses on representing public and private companies, including start-ups, in complex partnering and licensing arrangements, mergers and acquisitions, spin-outs, collaboration agreements, license agreements with academic and nonprofit institutions, research and development agreements, clinical trial agreements, and manufacturing, supply, and distribution agreements.
- J.D., UCLA School of LawChief Articles Editor, UCLA Journal of Law and Technology
- B.A., Human Biology, Stanford UniversityMinor in Modern Languages
- State Bar of California
- J.D., UCLA School of LawChief Articles Editor, UCLA Journal of Law and Technology
- B.A., Human Biology, Stanford UniversityMinor in Modern Languages
- State Bar of California
Adzenys XR-ODT extended-release orally disintegrating tablets is a prescription medicine used for the treatment of attention deficit hyperactivity disorder (ADHD) in patients 6 years and above and the only brand FDA-approved as bioequivalent to Adderall XR®. Cotempla XR-ODT is the only extended-release orally disintegrating tablet methylphenidate and is FDA-approved as a once-daily ADHD treatment for patients 6 to 17 years of age. Aytu's ADHD portfolio has experienced rapid growth over the past two years, with prescriptions increasing 16.5 percent during that time. This agreement extends Aytu's reach through the expansion into one of the world's largest ADHD markets outside the United States. In 2023, the Canadian ADHD stimulant market recorded 4.5 million units and $1.1 Billion CAD in gross sales. (Source: IQVIA Canada). Lupin will seek local regulatory approvals and marketing authorizations for both Adzenys XR-ODT and Cotempla XR-ODT, which is expected to occur over the next 18 to 24 months.
- Privacy Policy
- Terms of Use
- Accessibility